Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
about
Targeted therapy for HM1.24 (CD317) on multiple myeloma cellsPeripheral T-cell lymphoma complicated by immunoglobulin A pemphigus: A case report and literature review.Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro.Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28- T-cells.
P2860
Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Thalidomide maintenance therap ...... atients with multiple myeloma.
@en
Thalidomide maintenance therap ...... atients with multiple myeloma.
@nl
type
label
Thalidomide maintenance therap ...... atients with multiple myeloma.
@en
Thalidomide maintenance therap ...... atients with multiple myeloma.
@nl
prefLabel
Thalidomide maintenance therap ...... atients with multiple myeloma.
@en
Thalidomide maintenance therap ...... atients with multiple myeloma.
@nl
P2093
P50
P1476
Thalidomide maintenance therap ...... atients with multiple myeloma.
@en
P2093
Anthony D Ho
Bernard Klein
Brigitte Neuber
Isabelle Herth
Jürgen Haas
Melanie Engelhardt
Michael Hundemer
Philipp Beckhove
Tobias Meissner
P304
P356
10.1016/J.EXPHEM.2012.10.018
P577
2012-11-08T00:00:00Z